Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas

[1]  Xuezhi Dong,et al.  Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. , 2017, Journal of neurosurgery.

[2]  M. J. van den Bent,et al.  Imaging Correlates of Adult Glioma Genotypes. , 2017, Radiology.

[3]  D. Oldridge,et al.  MRI features predict survival and molecular markers in diffuse lower-grade gliomas , 2017, Neuro-oncology.

[4]  T. Cloughesy,et al.  Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas , 2017, Journal of Neuro-Oncology.

[5]  H. Duffau,et al.  IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas , 2017, Journal of Neuro-Oncology.

[6]  D. Dong,et al.  Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma , 2017, Clinical Cancer Research.

[7]  Eun Sook Ko,et al.  Breast cancer heterogeneity: MR Imaging Texture Analysis and Survival Outcomes1 , 2016 .

[8]  Chuong D. Hoang,et al.  Predictive radiogenomics modeling of EGFR mutation status in lung cancer , 2017, Scientific Reports.

[9]  Yuanyuan Wang,et al.  Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas , 2017, The International journal of neuroscience.

[10]  Leland S. Hu,et al.  Radiogenomics to characterize regional genetic heterogeneity in glioblastoma , 2016, Neuro-oncology.

[11]  Raymond Y Huang,et al.  Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas , 2017, Neuro-oncology.

[12]  Yuanyuan Wang,et al.  Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma , 2017, European Radiology.

[13]  Naoki Kagawa,et al.  Introduction of High Throughput Magnetic Resonance T2-Weighted Image Texture Analysis for WHO Grade 2 and 3 Gliomas , 2016, PloS one.

[14]  V. Coenen,et al.  Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma – A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy , 2016, Scientific Reports.

[15]  E. Miyaoka,et al.  A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas , 2016, Acta neuropathologica communications.

[16]  T. Tominaga,et al.  Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion , 2016, Journal of Neuro-Oncology.

[17]  M. Götz,et al.  Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. , 2016, Radiology.

[18]  Erich P Huang,et al.  MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. , 2016, Radiology.

[19]  Walter J. Curran,et al.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. , 2016, The New England journal of medicine.

[20]  S. Heiland,et al.  IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma , 2015, Scientific Reports.

[21]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[22]  Satoru Miyano,et al.  Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.

[23]  Ryuta Saito,et al.  Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas , 2015, Brain Tumor Pathology.

[24]  Y. Kodama,et al.  11C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas , 2014, Clinical Neurology and Neurosurgery.

[25]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[26]  S. Plevritis,et al.  Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. , 2014, Radiology.

[27]  T. Yoshimine,et al.  Different spatial distribution between germinal center B and non-germinal center B primary central nervous system lymphoma revealed by magnetic resonance group analysis. , 2014, Neuro-oncology.

[28]  Neema Jamshidi,et al.  Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. , 2013, Radiology.

[29]  B. Rosen,et al.  Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. , 2013, The Journal of clinical investigation.

[30]  E. Melhem,et al.  Differentiation between Oligodendroglioma Genotypes Using Dynamic Susceptibility Contrast Perfusion-Weighted Imaging and Proton MR Spectroscopy , 2013, American Journal of Neuroradiology.

[31]  H. Iseki,et al.  Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype. , 2013, Neurologia medico-chirurgica.

[32]  Luc Taillandier,et al.  Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. , 2013, Journal of neurosurgery.

[33]  T. Cloughesy,et al.  Probabilistic Radiographic Atlas of Glioblastoma Phenotypes , 2013, American Journal of Neuroradiology.

[34]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Robert J. Harris,et al.  Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas , 2012, NeuroImage.

[36]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[37]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[38]  K. Chang,et al.  Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[39]  Sylvia Drabycz,et al.  An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging , 2010, NeuroImage.

[40]  Bruce Fischl,et al.  Accurate and robust brain image alignment using boundary-based registration , 2009, NeuroImage.

[41]  D. Demetrick,et al.  The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma , 2008, Clinical Cancer Research.

[42]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[44]  Michael Brady,et al.  Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images , 2002, NeuroImage.

[45]  J Mazziotta,et al.  A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[46]  Stephen M. Smith,et al.  A global optimisation method for robust affine registration of brain images , 2001, Medical Image Anal..

[47]  Arthur W. Toga,et al.  A Probabilistic Atlas of the Human Brain: Theory and Rationale for Its Development The International Consortium for Brain Mapping (ICBM) , 1995, NeuroImage.

[48]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.